Thursday, July 30, 2015

Best Specialty Retail Stocks To Buy Right Now

Best Specialty Retail Stocks To Buy Right Now: Ulta Salon Cosmetics and Fragrance Inc (ULTA)

Ulta Salon, Cosmetics & Fragrance, Inc. (Ulta), incorporated on January 9, 1990, is a beauty retailer, which provides one-stop shopping for prestige, mass and salon products and salon services in the United States. During the year ended January 28, 2012 (fiscal 2011), the Company opened 61 new stores. It operates full-service salons in all of its stores. Its Ulta store format includes an open and modern salon area with approximately eight to 10 stations. The entire salon area is approximately 950 square feet with a concierge desk, skin treatment room, semi-private shampoo and hair color processing areas. Each salon is a full-service salon offering hair cuts, hair coloring and permanent texture, with salons also providing facials and waxing.

The Company offers products in the categories, such as cosmetics, which includes products for the face, eyes, cheeks, lips and nails; haircare, which includes shampoos, conditioners, styling products, and hair accessories; salon styling tools, which includes hair dryers, curling irons and flat irons; skincare and bath and body, which includes products for the face, hands and body; fragrance for both men and women; private label, consisting of Ulta branded cosmetics, skincare, bath and body products and haircare, and other, including candles, home fragrance products and other miscellaneous health and beauty products. The Company has combined its three operating segments: retail stores, salon services and e-commerce, into one reportable segment.

The Company competes with Macy's, Nordstrom, Sephora, Bath & Body Works, CVS/pharmacy, Walgreens, Target, Wal-Mart, Regis Corp., Sally Beauty and JCPenney salons.

Advisors' Opinion:
  • [By Jonas Elmerraji]

     

     

    Nearest Resistance: $130

    N! earest Support: $100

    Catalyst: Q2 Earnings

     

    Shares of beauty supply operator Ulta Salon, Cosmetics & Fragrance (ULTA) moved up approximately 20% in Friday's session, boosted by positive second quarter earnings numbers. Ulta reported profits for 94 cents per share for the quarter, beating out analysts' best guess profits of 83 cents per share. Even better, the firm expects third quarter revenues on the high end of Wall Street's expectations for both revenue and profits.

     

    The technicals look good in ULTA right now. This stock's big gap higher on Friday broke shares above key round-number resistance at $100, clearing the way for a retest of last year's highs up near $130. For traders who aren't risk-averse, ULTA is buyable here.

     

    Read More: 5 Stocks With Big Insider Buying

     

  • [By Luke Jacobi]

    Shares of ULTA Salon, Cosmetics & Fragrance (NASDAQ: ULTA) got a boost, shooting up 17.9 percent to $114.89 after the company reported upbeat second-quarter results and raised its outlook. The company also unveiled a five-year plan for impressive growth.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/best-specialty-retail-stocks-to-buy-right-now-2.html

Thursday, July 23, 2015

9 Winning Retail Stocks You Can Scout at the Mall

The greatest mutual fund manager of the 20th century once explained a secret to his success: "I began my search for new selections in the usual fashion. I headed straight for my favorite source of investment ideas: the Burlington Mall."

See Also: Enticing Dividend-Paying Stock Picks

Those are the words of Peter Lynch, manager of Fidelity Magellan in its heyday, from 1977 to 1990, when the fund racked up an annualized return of 29%—twice the rate of Standard & Poor's 500-stock index. In a series of books that Lynch wrote after he retired, he said that if individual investors would put the "power of common knowledge" to work, they could gain an edge over professionals. Look around you and, as the subtitle of Lynch's One Up on Wall Street put it, "use what you already know."

Lynch went on: "I stumble onto the big winner in extracurricular situations, the way you could: Taco Bell, I was impressed with the burrito on a trip to California…Dunkin' Donuts, I loved the coffee; and recently the revamped Pier 1 Imports, recommended by my wife. In fact, Carolyn is one of my best sources. She's the one who discovered L'eggs."

Egg-cellent. Carolyn found the pantyhose in an ovoid plastic container, sold in supermarkets, and Peter invested in the manufacturer, Hanes Corp. "It turned out to be a six-bagger," he wrote, meaning that Lynch's investment in Hanes sextupled in value before the company was acquired. Lynch essentially was making the same point that Yogi Berra once did: "You can see a lot just by looking." And nowhere is looking a more powerful tool than in retailing.

We all go to the equivalent of Burlington Mall, which is located in Burlington, Mass., and we all have opinions about where we get good quality, selection and service. We can see which stores have a lot of foot traffic, and which have imaginative merchandising and appealing prices. Do such attributes translate into strong profits? Not always. But looking is the starting point.

Unfortunately, many of the best retailers, including Neiman Marcus, Toms Shoes and J. Crew, are privately owned. But that leaves scores of smaller retail chains for you to ferret out.

Michael Kors Holdings (KORS) is a good example of what you can find. Based in Hong Kong but with corporate offices in New York City, Kors designs men's and women's apparel and accessories—high-end but not outrageously priced—and sells them in more than 200 of its own retail stores around the world, as well as in more than 2,000 department stores. If you shop at Kors, you know that the chain's merchandise has caught fire in recent years—especially its terrific women's clothes, shoes and logo-heavy handbags. They're sold in what my fashion-editor daughter calls "stores that are all polished chrome and mirrors, very glam and eye-catching."

When the company went public on December 15, 2011, Michael Kors, along with private-equity investors, scored a windfall. But Kors remained with the firm as its chief creative officer. John Idol, the highly regarded CEO, stayed, too. The stock has soared, rising from a close of $24.20 on its first day of trading to $69 today (all prices are as of August 2). But even if you missed investing in a near-three-bagger, Kors is still attractive. Revenues rose 68% for the fiscal year that ended March 30, and earnings jumped from 78 cents to $1.97 per share. The stock's price-earnings ratio, based on estimated profits, is 27—perfectly reasonable for a company growing so fast.

The best retailers, like the best handbags, don't come cheap, so look to buy on dips. Lululemon Athletica (LULU), the Vancouver, Can.–based purveyor of gloriously colored yoga outfits that has a cultlike following, took a huge dive, from $82 to $61, during a two-week period in June—after the CEO resigned on the heels of the embarrassing revelation that a fabric used in Lululemon clothes was too easy to see through. The stock, which has recovered to $73, still isn't cheap, at 36 times estimated earnings for the fiscal year that ends next January. But analysts expect earnings to jump a robust 29% the following year, suggesting that the stock is reasonably priced.

Lululemon and Michael Kors have the power of quality and personality on their side, helping them to ward off competitors and allowing them to charge premium prices. That description also fits Tumi Holdings (TUMI), which sells the luggage it makes through 114 company-owned stores and another 1,700 distribution points in 75 countries. Tumi went public in April 2012 at $18, soared to $26.50 on its first day of trading and is now at $25. The stock's price-earnings ratio—29, based on estimated 2013 earnings—seems reasonable, given that analysts expect earnings to rise by 25% next year.

As for what my own eyes have seen, the world has two great luxury retailers. The first is Hermès International (HESAY), which has perfected the art of charging high prices by limiting the supply of hugely desirable items. With 25 stores in the U.S. and another 300 in other countries, the Paris-based company charges $10,000 and up for its Birkin handbags, and the waiting list for these and other hot products is often more than a year. The company swatted away the 2007–09 recession like a pesky mosquito. Revenues have doubled since 2007, and profits rose from 288 million euros to 740 million euros (about $979 million).

5 Best Managed Healthcare Stocks To Buy Right Now

Hermès's American depositary receipts trade on the pink sheets—the non-Nasdaq over-the-counter market—which means volume is limited. Still, your broker should be able to buy the stock for you, either here or on the bourse in Paris. A bonus of owning the stock, which goes for $35, is that you'll receive the most gorgeous annual report you'll ever see.

My second favorite is Loro Piana, the Italian maker of fine scarves, sweaters and other apparel, with 17 stores in the U.S. and hundreds of others around the world, including ten in China. The family that owned Loro Piana sold it in July for $2.6 billion to LVMH Moët Hennessy Louis Vuitton (LVMUY), the largest luxury retail conglomerate in the world. LVMH owns the eponymous leather-goods and wine makers, as well as retail brands such as Céline, Thomas Pink, Pucci, the Sephora cosmetics chain and many more. LVMH, whose ADRs trade for $37, has been accumulating shares of Hermès and now owns nearly 25% of the firm.

Let's go downscale a bit to Zara, whose success is evident once you step into a store. The shoppers who jam its stores can, says my daughter, "get on-trend items that look chic and expensive, with a sleek, tailored European cut, but you're spending an average of less than $300 for three or four pieces." Zara is the flagship chain of Spain's Industria de Diseño Textil (IDEXY), or Inditex Group, which is also introducing Massimo Dutti, another superb, more upscale chain, to America. Of Zara's 1,763 stores, 44 are in the U.S. Inditex's ADRs trade for $27.

Another consumer favorite is Destination Maternity (DEST), which owns A Pea in the Pod and other chains (a total of 606 stores) for expectant mothers. At $30, the stock is well priced and delivers an above-average dividend yield of 2.5%. Williams-Sonoma (WSM), the cream of the kitchen-gadget purveyors, charges premium prices and offers superb service—plus extravagant catalogs and a great Web site. The stock fetches $61 and yields 2.0%. Also providing a welcoming experience for consumers is Home Depot (HD), the best of the big-box stores. I recommended the stock in the December 2012 issue of Kiplinger's at three-fourths its current price of $80, and I still like it.

Take my advice, or better yet, look for your own winners. Just remember that when you go to the mall, keep your eye out for stock bargains, too.

James K. Glassman is the founding executive director of the George W. Bush Institute in Dallas. He owns none of the stocks mentioned.



Tuesday, July 21, 2015

Top 5 Long Term Stocks To Buy Right Now

Top 5 Long Term Stocks To Buy Right Now: NTELOS Holdings Corp.(NTLS)

NTELOS Holdings Corp., through its subsidiaries, provides wireless communications services to consumers and businesses primarily in Virginia and West Virginia, as well as parts of Maryland, North Carolina, Pennsylvania, Ohio, and Kentucky. It primarily offers wireless digital personal communications services, such as wireless voice and data products and services, and roaming/travel services under the NTELOS Wireless brand name. The company also provides wholesale network services to Sprint Nextel in the western Virginia and West Virginia area for various Sprint CDMA wireless customers. As of March 6, 2012, its wireless retail business had approximately 415,000 postpay and prepaid subscribers. The company was founded in 1897 and is headquartered in Waynesboro, Virginia.

Advisors' Opinion:
  • [By Lauren Pollock]

    Ntelos Holdings Corp.(NTLS) said it had settled disputes with Sprint Corp.(S) related to the companies’ strategic network alliance. The settlement resolves a dispute over the reset of data rates that began in the fourth quarter of 2011, as well as unrelated billing disputes raised in the third quarter of 2012. Shares of Ntelos were up 9.7% at $17.50 in after-hours trading.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-long-term-stocks-to-buy-right-now-2.html

Thursday, July 9, 2015

5 Best Biotech Stocks To Watch For 2015

Leerink’s Howard Liang and team think 2015 will be another good year for biotech stocks like Gilead Sciences (GILD), Celgene (CELG), Amgen (AMGN ) and Alexion Pharmaceuticals (ALXN). They explain why:

Boston Globe via Getty Images

Biotech fundamentals appear strong, and could attract and broaden investor interest in the sector. Ongoing and upcoming product launches could be among the fastest in history. Data releases and M&A both still provide ample opportunities for upside…

The fundamentals of the biotech industry appear strong as measured by a robust list of ongoing and expected product launches. Large-cap biotech companies under our coverage (Alexion Pharmaceuticals, Amgen, Celgene, Gilead, Vertex Pharmaceuticals (VRTX)) all have ongoing or anticipated product launches in 2015. These launches…AbbVie (ABBV) /�Enanta Pharmaceuticals (ENTA) Viekirax + Exviera for hepatitis C…Other high-visibility launches include the expected launches of PCSK9 antibodies, evolocumab from�Amgen and alirocumab from Sanofi (SNY) / Regeneron (REGN) for high cholesterol, anticipated in 3Q:15. Although the expectation is for a slow ramp-up until cardiovascular outcome data (no later than 2017), the market is large enough to allow fast launches. For Celgene, Gilead, Medivation (MDVN) and Vertex, the launches are for their most important products; therefore the progress of the launches will be particularly important to watch.

Top 5 Construction Stocks For 2016: Cannabis Science Inc (CBIS)

Cannabis Science, Inc., incorporated on May 4, 2007, is a development-stage company. The Company is engaged in the creation of cannabis-based medicines, both with and without psychoactive properties, to treats disease and the symptoms of disease, as well as for general health maintenance. On February 9, 2012, the Company acquired GGECO University, Inc. (GGECO). On March 21, 2012, the Company acquired Cannabis Consulting Inc. (CCI Group).

The Company is engaged in medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.

Advisors' Opinion:
  • [By Bryan Murphy]

    The last few days have been nothing less than incredible for stocks like Cannabis Science Inc. (OTCMKTS:CBIS), Medbox Inc. (OTCMKTS:MDBX), Growlife Inc. (OTCBB:PHOT), and Medical Marijuana Inc. (OTCMKTS:MJNA). MJNA shares have jumped 90% since last Friday. PHOT is up 51% for the same timeframe. CBIS has grown 150%, while MDBX is up 112%. The reason? It's largely the legalization of recreational marijuana in Colorado - a law that went into effect as of January 1st. The legalization of medical marijuana in Illinois on the same day didn't hurt either. And truth be told, the event-based rally from the likes of Medbox and Cannabis Science makes basic sense - it's a landmark shift in the way this country views and treats marijuana. On the flipside, before wading any deeper into stocks like Medical Marijuana or Growlife, current and would-be owners might want to take a step back and look at the bigger picture.

  • [By Bryan Murphy]

    The difference between Growlife's leadership and, say that of competitors like Cannabis Science Inc. (OTCMKTS: CBIS) or Medical Marijuana Inc. (OTCMKTS: MJNA), has been relatively well documented here at the SmallCap Network site. I think the way I - well, someone else - put it back on June 25th says it best...."Growlife is sort of the demure girl in the corner who doesn't do shots off her navel in the bar." It may not have sizzle, but it does have substance.

  • [By John Udovich]

    Although its summer, there has been a steady stream of good news about medical marijuana even though important small cap marijuana stocks�Medical Marijuana Inc (OTCMKTS: MJNA) and Cannabis Science Inc (OTCMKTS: CBIS) have been fairly quietly lately while Growlife Inc (OTCBB: PHOT), a more indirect play on the spread of legalized marijuana, has produced�some news for investors:

  • [By Bryan Murphy]

    There's no denying it. Marijuana stocks like Cannabis Science Inc. (OTCMKTS:CBIS), Growlife Inc. (OTCBB:PHOT), and Medical Marijuana Inc. (OTCMKTS:MJNA) have gotten their second wind (and some would argue their third wind) over the past few days, doling out big gains in a very short period of time. MJNA is up 88% over the past four trading days, counting today. PHOT has popped 44% during that timeframe. CBIS has advanced 91% in just six days. It's everything a devoted shareholder of any of these companies could hope for, and more.

5 Best Biotech Stocks To Watch For 2015: Regeneron Pharmaceuticals Inc.(REGN)

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company?s commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consist of VEGF Trap-Eye, an aflibercept ophthalmic solution developed using intraocular delivery for the treatment of serious eye diseases; ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment; and Aflibercept (VEGF Trap), which is developed in oncology. The company?s earlier stage clinical programs include various human antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction, REGN88 for rheumatoid arthritis and ankylosing spondylitis; REGN668 for atopic dermatitis and asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; and REGN728 and REGN846. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize VEGF Trap. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is based in Tarrytown, New York.

Advisors' Opinion:
  • [By Ben Levisohn]

    On a quiet day for big biotech, shares of Celgene have fallen 0.2% to $94.73 at 10:58 a.m., while Amgen (AMGN) has gained 0.1% to $138.69, Gilead Sciences (GILD) has dipped 0.1% to $109.33, Biogen Idec (BIIB) has dropped 0.7% to $34167 and Regeneron (REGN) is off 0.9% at $358.76.

5 Best Biotech Stocks To Watch For 2015: Ophthotech Corp (OPHT)

Ophthotech Corporation, incorporated on January 05, 2007, is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye. The Company�� advanced product candidate is Fovista, which the Company is developing for use in combination with anti-VEGF drugs that represent the current standard of care for the treatment of wet age-related macular degeneration (wet AMD). Wet AMD is a serious disease of the central portion of the retina, known as the macula, which is responsible for detailed central vision and color perception. It is characterized by abnormal new blood vessel formation and growth, referred to as neovascularization, which results in blood vessel leakage, retinal distortion and scar formation. If untreated, the progressive retinal damage results in rapid, irreversible and severe vision loss. Wet AMD is the cause of blindness in patients over the age of 55 in the United States and the European Union.

The anti-VEGF market for the treatment of wet AMD consists predominantly of two drugs that are approved for marketing and primarily prescribed for the treatment of wet AMD, Lucentis and Eylea, and off-label use of the cancer therapy Avastin. The use of anti-VEGF drugs has significantly improved visual outcomes for patients with wet AMD who have been treated with these drugs as compared to untreated patients.

Advisors' Opinion:
  • [By John Udovich]

    The biotech sector has been pretty exciting this year�with small cap biotech stocks Prana Biotechnology Limited (NASDAQ: PRAN) and TNI BioTech (OTCMKTS: TNIB) having recently produced noteworthy news for investors�while Acceleron Pharma, Inc (NASDAQ: XLRN), Ophthotech (NASDAQ: OPHT) and BIND Therapeutics (NASDAQ: BIND) have just�set term sheets for their upcoming IPOs. Just consider all of the following recent news:

  • [By John Udovich]

    If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:

  • [By Todd Campbell]

    That leads me to Medivation (NASDAQ: MDVN  ) , Ophthotech (NASDAQ: OPHT  ) , and Portola (NASDAQ: PTLA  ) , three companies with important therapies that may very well be destined to become top sellers.

5 Best Biotech Stocks To Watch For 2015: OncoGenex Pharmaceuticals Inc.(OGXI)

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company?s clinical stage products include Custirsen, a phase III clinical stage product for treatment in men with metastatic castrate-resistant prostate cancer; OGX-427, which is in phase II clinical development stage is designed to inhibit heat shock protein 27; and SN2310 that completed phase I stage of clinical development is designed to evaluate safety in patients with advanced cancer. Its pre clinical stage products include GX-225 that is focused on reducing the production of IGFBP-2 and IGFBP-5; and CSP-9222, lead compound from a family of caspase activators. OncoGenex Pharmaceuticals, Inc. is based in Bothell, Washington.

Advisors' Opinion:
  • [By Lauren Pollock var popups = dojo.query(".socialByline .popC"); popups.forEach]

    Teva Pharmaceutical Industries Ltd.(TEVA) and OncoGenex Pharmaceuticals Inc.(OGXI) said their experimental drug for hard-to-treat cases of prostate cancer didn’t result in statistically significant improvement in overall survival in a Phase 3 study. OncoGenex shares dropped 48% to $5 premarket.

Thursday, July 2, 2015

Best High Tech Companies To Own For 2016

Best High Tech Companies To Own For 2016: Danieli & C Officine Meccaniche SpA (DAS)

Danieli & C Officine Meccaniche SpA is an Italy-based company primarily engaged in industrial sector. The Company designs, manufactures, sales and makes installation of machines and plants for the metallurgical industry. The Company's portfolio includes mines; pellet production plants; blast furnaces; direct reduction equipment; machinery for the treatment of scrap metal; steelworks for production of liquid steel; continuous casting machinery for blooms, billets and slabs; rolling mills for long products, seamless tubes and flat products; production lines for welded tubes and flat products; plants for secondary processing, such as peeling, rolling and drawing; forging presses and manipulators; extrusion presses for ferrous and non-ferrous metals; plants for longitudinal and transversal cutting; automation and control systems, and cranes and lifting equipment. It is also active in the production and sale of special steel for automotive, machine tools and railway industry, amon g others. Advisors' Opinion:
  • [By Damian Illia]

    Crown Castle has acquired recently the privately held company NextG Networks Inc., largest provider of outdoor Distributed Antenna Systems (DAS), with more than 7,000 DAS plus another 1,500 nodes in the pipeline, and over 4,600 miles fiber-optic cable's transmission rights. Through this addition, the company has improved greatly its DAS network across 26 United States metropolitan areas. As NextG has only 1.7 tenants per network on an average and thus underutilizing its capacity, Crown Castle will increase customers with no integration and rearrangement costs. Another company's big move was the acquisition of 9,700 wireless towers from AT&T Inc. (T) Located in the top 100 markets in the U. S. T-Mobile is likely to maintain its infrastructure in these towers for the next 10 ye! ars. On top of all, the recent conversion of business into a REIT has represented long term benefits for the company in terms of tax savings and enhancing shareholders' wealth.

  • [By GURUFOCUS]

    EMC's products – both hardware and software - are litearlly a geek's wonderland alphabet soup, which include Storage Area Network (SAN), Network Attached Storage (NAS), Direct Attached Storage (DAS), Virtual SAN, All-Flash XtremIO, Atmos, Avamar,  Data Domain, Isilon, Pivotal, ViPR Software Defined Storgae, VMAX, VNX, VNXe, VPLEX, VSPEX (none of these are typos).  Information storage makes up 70% of revenues and virtualization 23% of revenues.  Products generate 55% of revenues.  Services generate 45% of revenues.  The Company's gross profit split is approximaltey 67% data storage and 31% virtualization.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/best-high-tech-companies-to-own-for-2016.html

Wednesday, July 1, 2015

Students panic over online college application glitches

common application college

Students are anxious that their college applications won't be received in time for early deadlines.

NEW YORK (CNNMoney) The college applications process is fraught with anxiety for students.

The last thing they need is a major technological glitch.

But in recent months, students across the country have encountered numerous glitches in the Common Application site they use to apply to more than 500 colleges and universities.

The site wouldn't let them submit forms, deleted entire portions of essays, and at times even charged twice for the same application. In some cases, students who thought they submitted applications learned that they hadn't even gone through.

It has caused a wave of concern among students and families who are applying early to colleges this year. The early applications are due for most colleges in mid-October through early November.

"I can't log into my Common App. It says my user name and password is incorrect even though it is not, and when I click 'forget password,' it does not send a reset link," Ramya Rupanagudi wrote on Common App's Facebook (FB, Fortune 500) page.

Matt Walz wrote that his entire essay was deleted and that he had to spend an hour retyping what he lost. Cathy Wood's daughter couldn't upload her letter of recommendation. Margaret Owens Rieger said that colleges she applied to never received her transcripts or essays. Evan Benford was charged twice.

5 Best Gas Utility Stocks To Buy Right Now

The Common App lets students fill out a single application for multiple colleges, including the vast majority of the country's top-tier schools. The site's popularity has skyrocketed, with the number of applicants nearly doubling in the last five years to more 700,000.

The website's software was overhauled in August. Since then, students and universities have experienced a litany of issues.

The site lists about 15 problems in the "Known Issues" page. All of them are in the process of being fixed, the site says.

But many students are worried that it will be too late.

Huai Julie wrote on Facebook that she was having troubl! e submitting her application.

"If this problem cannot be solved, it means I will [lose] my application opportunity," she wrote.

Some colleges have taken steps to address the issue, warning of the processing problems in their own websites. Others, like The University of North Carolina and Georgia Tech, extended their deadlines from from Oct. 15 to Oct. 21.

"We are in regular communication with the Common Application, which is doing their best to resolve these issues," UNC's wesbsite said.

Common Application did not respond to requests for comment. To top of page